ERFURT/BERLIN/DENSBORN,
Germany, and LEAMINGTON, ON, Canada, Jan. 26,
2021 /CNW/ - AMP German Cannabis Group Inc.
("AMP") (CSE: XCX), (Frankfurt: C4T) (ISIN: CA00176G1028) and
Aphria Inc.'s ("Aphria") (TSX: APHA) (NASDAQ: APHA)
wholly-owned German subsidiary, CC Pharma GmbH ("CC
Pharma"), have entered into a strategic agreement (the
"Co-Promotion Agreement") covering joint marketing of sales
for Aphria brand medical cannabis products for the German
market.
The Co-Promotion Agreement is a collaboration contract between
AMP and CC Pharma to sell the Aphria medical cannabis brand in
Germany. In addition, AMP will
organize with the support of CC Pharma, "information events" in
Germany to market Aphria branded
products to doctors and pharmacists.
Hendrik Knopp, Managing Director
of Aphria Germany GmbH mentioned, "We are proud to launch our
high-quality medical cannabis under the Aphria brand in
Germany with the support of AMP.
This agreement provides the opportunity to expand the Aphria brand
in Germany, one of our key
international markets."
Dr. Stefan Feuerstein, Director
and President of AMP, commented, "We are proud to partner with
Aphria and CC Pharma GmbH. Our sole focus is to sell medical
cannabis in Germany, which makes
us an ideal partner to co-promote and sell the Aphria brand.
In preparation for this partnership, we have significantly expanded
our sales team to sell the Aphria and AMP brands as well as other
branded medical cannabis products across Germany."
About Aphria Inc.
Aphria Inc. is a leading global cannabis-lifestyle consumer
packaged goods company with operations in Canada, United
States, Europe, and
Latin America, that is changing
people's lives for the better – one person at a time – by inspiring
and empowering the worldwide community to live their very best life
by providing them with products that meet the needs of their mind,
body and soul and invoke a sense of wellbeing. Aphria's mission is
to be the trusted partner for its patients and consumers by
providing them with a cultivated experience and health and
wellbeing through high-quality, differentiated brands and
innovative products.
Headquartered in Leamington,
Ontario, Aphria cultivates, processes, markets and sells
medical and adult-use cannabis, cannabis-derived extracts and
derivative cannabis products in Canada under the provisions of the Cannabis
Act and globally pursuant to applicable international regulations.
Aphria also manufactures, markets and sells alcoholic beverages in
the United States. For more
information, please visit: https://aphria.ca.
About CC Pharma GmbH
Founded in 1999, CC Pharma is based in Densborn, Germany and is one of the leading national
distributors of pharmaceutical products to pharmacists in
Germany, with over 13,000
pharmacies in its sales network. For more information, please
visit: www.cc-pharma.de.
About AMP German Cannabis Group
AMP German Cannabis Group is licensed to import European Union -
Good Manufacturing Practice (EU-GMP) medical cannabis from
Europe and elsewhere into
Germany. AMP sources, stores,
transports, delivers, and sells medical cannabis products to
pharmaceutical distributors or pharmacists directly, the only
point-of-sale for medical cannabis to German patients with a
physician's prescription. AMP has entered into a non-exclusive
distribution agreement for medical cannabis with a leading
distributor of pharmaceuticals products to more than 13,000
pharmacies throughout Germany.
AMP has sponsored a six-episode roundtable discussion series
about medical cannabis in Germany.
The Roundtable Series is available by podcast or video. In Episode
#2 titled, "Politics and Medical Cannabis in Germany", Dr. Wieland Schinnenburg, MdB (FDP)
provides an up-to-date overview of the political issues and
challenges facing the medical cannabis industry in Germany. The panel also includes Dr.
Stefan Feuerstein, President of AMP
and Mr. Holger Scholze as moderator.
AMP Roundtable Series: www.amp-eu.de/roundtable
For more information, please visit: www.amp-eu.com
Aphria Inc. social media links:
- Twitter: https://twitter.com/aphriainc
- LinkedIn: https://www.linkedin.com/company/aphriainc
- Facebook: https://www.facebook.com/aphriaMMJ
AMP social media links:
- Twitter: https://twitter.com/AMP_Cannabis
-
LinkedIn: www.linkedin.com/company/ampgermancannabisgroup
- Facebook: www.facebook.com/AMPGCG
- Instagram: www.instagram.com/ampgcg
- Podcast: http://ow.ly/EqBc50BJ4xw
Media Kit: www.amp-eu.com/media-kit
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
information or forward-looking statements (together,
"forward-looking statements") under applicable securities laws and
are expressly qualified by this cautionary statement. Any
information or statements that are contained in this news release
that are not statements of historical fact may be deemed to be
forward-looking statements, including, but not limited to,
statements in this news release with regards to the expected impact
of the EU GMP certification on the Company's business and
expectations related to the Company's market position. The Company
uses words such as "forecast", "future", "should", "could",
"enable", "potential", "contemplate", "believe", "anticipate",
"estimate", "plan", "expect", "intend", "may", "project", "will",
"would" and the negative of these terms or similar expressions to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Various
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this news release.
Forward-looking statements reflect management's current beliefs
with respect to future events and are based on information
currently available to management including based on reasonable
assumptions, estimates, internal and external analysis and opinions
of management considering its experience, perception of trends,
current conditions and expected developments as well as other
factors that management believes to be relevant as at the date such
statements are made. Forward-looking statements involve significant
known and unknown risks and uncertainties. Many factors could cause
actual results, performance or achievement to be materially
different from any future forward-looking statements. Factors that
may cause such differences include, but are not limited to, risks
associated with COVID-19 nationally and globally which could have a
material adverse impact on Aphria's business, operations and
financial results, including disruptions in the supply chains and
sales channels, as well as a deterioration of general economic
conditions including national and/or global recessions and the
response of governments to the COVID-19 pandemic in respect of the
operation of retail stores; general economic conditions; adverse
industry events; marketing costs; loss of markets; future
legislative and regulatory developments involving cannabis or
otherwise affecting Aphria's business or its consumers generally;
inability to access sufficient capital from internal and external
sources; income tax and regulatory matters, including delays in the
issuance of licenses; the sale and distribution of vapes; the
ability of Aphria to meet its liquidity requirements to fund
ongoing operations; the ability of Aphria to implement its business
strategies; competition; currency and interest rate
fluctuations.
Readers are cautioned that the foregoing list is not exhaustive
and should carefully review the various risks and uncertainties
identified in the Company's filings on SEDAR and EDGAR. Readers are
further cautioned not to place undue reliance on forward-looking
statements as there can be no assurance that the plans, intentions
or expectations upon which they are placed will occur. Such
information, although considered reasonable by management at the
time of preparation, may prove to be incorrect and actual results
may differ materially from those anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Neither TSX nor its Regulation Services Provider (as that term is
defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release. In
addition, neither the CSE nor its Regulation Services Provider (as
that term is defined in the policies of the CSE) accepts
responsibility for the adequacy or accuracy of this
release.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE AMP German Cannabis Group Inc.
